If you are on medication for osteoporosis, are you ever tempted to stop taking it? If your answer is yes, you are not alone. Studies indicate that especially for those […]

The Accessible Canada Directorate within Employment and Social Development Canada (ESDC) has engaged Quorus Consulting Group to conduct the second cycle of public opinion research measuring Canadians’ awareness and experience(s) […]

Last week, Osteoporosis Canada heard a news story that suggested that there is an increased risk of developing osteonecrosis of bone if you are taking a bisphosphonate medication for osteoporosis. […]

The B.C. Ministry of Health is conducting a survey of patients, caregivers, and advocacy groups to achieve input regarding osteoporosis therapies in British Columbia and B.C. PharmaCare coverage. We know […]

Osteoporosis Canada is saddened to announce the passing of Dr. Timothy M. Murray, founding member of Osteoporosis Canada. Dr. Murray was the Emeritus Professor of Medicine at the University of […]

There has been recent media coverage concerning a rare atypical femoral fracture that may be a side effect of denosumab (Prolia), an osteoporosis medication manufactured by Amgen. Osteoporosis Canada’s Scientific […]

Denosumab A human monoclonal antibody that prevents RANKL-RANK interaction Denosumab (Bone Metabolism Regulator) Denosumab is a new class of osteoporosis treatment called a human monoclonal antibody that prevents RANKL-RANK interaction […]

Contributors: Dr. Adrian Lau, Dr. Claudia Gagnon, Dr. Laëtitia Michou, Dr. Emma Billington, Dr. Zahra Bardai, Dr. Dr. Vithika Sivabalasundaram, Dr. Rowena Ridout, Dr. Sandra Kim, Dr. Suzanne Morin Recommendations […]

Dr. Marla Shapiro spoke at the recent CNS Day at World Congress on Osteoporosis, Osteoarthritis and Musculoskeletal Diseases (WCO-IOF-ESCEO Paris 2019) on patient empowerment. Watch this short video where Dr. […]